Navigation Links
Merrimack to Present New Analyses of Phase 3 NAPOLI-1 Data at the ESMO 18th World Congress on Gastrointestinal Cancer
Date:6/21/2016

CAMBRIDGE, Mass., June 21, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it will present new analyses of the Phase 3 NAPOLI-1 data in an oral presentation and poster discussion session at the European Society for Medical Oncology  (ESMO) 18th World Congress on Gastrointestinal Cancer, June 29 – July 2, 2016 in Barcelona, Spain. An oral presentation by Dr. Richard Hubner, Consultant Medical Oncologist, The Christie NHS Foundation Trust and investigator on the NAPOLI-1 trial, will compare the effects of ONIVYDE® (also known as "nal-IRI") in combination with fluorouracil and leucovorin on quality of life in patients with metastatic pancreatic adenocarcinoma previously treated with gemcitabine-based therapy versus treatment with fluorouracil and leucovorin alone.

Merrimack will also present an analysis of the NAPOLI-1 safety data across patient subgroups in a poster discussion session and a trials-in-progress poster on a Phase 2 study evaluating ONIVYDE containing regimens as first-line therapy for patients with metastatic pancreatic cancer.

Oral Presentation:

  • Effects of nal-IRI (MM-398) ± 5-fluorouracil on quality of life (QoL) in NAPOLI-1: A phase 3 study in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy (Abstract O-004)
    Wednesday, June 29, 2016, 5:53 - 6:03 PM CEST
    Session: Pancreatic Cancer
    Poster Presentation Time: Thursday, June 30, 2016, 11:00 - 11:30 AM and 5:10 - 5:40 PM CEST
    CCIB, Exhibit Hall

Poster Sessions:

  • Safety across subgroups in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy (Abstract PD-023)
    Session: Pancreatic Cancer
    Poster Discussion Time: Thursday, June 30, 2016, 11:00 - 11:30 AM CEST
    Poster Presentation Time: Thursday, June 30, 2016, 11:00 - 11:30 AM and 5:10 - 5:40 PM CEST
    CCIB, Exhibit Hall
  • Nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic adenocarcinoma (mPAC): A randomized, open-label phase 2 study (Abstract P-287)
    Session: Pancreatic Cancer
    Poster Presentation Time: Thursday, June 30, 2016, 11:00 - 11:30 AM and 5:10 - 5:40 PM CEST
    CCIB, Exhibit Hall

About Merrimack

Merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. Through systems biology, which brings together the fields of biology, computing and engineering, Merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. Such an approach has the potential to make individualized treatment of patients a reality. Merrimack's first commercial product, ONIVYDE® (irinotecan liposome injection), was approved by the U.S. FDA in October 2015. With four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, Merrimack is building one of the most robust oncology pipelines in the industry. For more information, please visit Merrimack's website at www.merrimack.com or connect on Twitter at @MerrimackPharma.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.

Contacts:
Media Contact
Marianne McMorrow
774-776-1478
mmcmorrow@merrimack.com

Investor Contact
Geoffrey Grande, CFA
617-441-7602
ggrande@merrimack.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/merrimack-to-present-new-analyses-of-phase-3-napoli-1-data-at-the-esmo-18th-world-congress-on-gastrointestinal-cancer-300288223.html


'/>"/>
SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Merrimack Reports Fourth Quarter 2015 Financial Results
2. Merrimack Announces Private Placement of $175 Million of Senior Secured Notes
3. Merrimack Amends MM-121 Phase 2 Clinical Study in Heregulin-Positive Non-Small Cell Lung Cancer to Support Potential Registration
4. Merrimack Reports Third Quarter 2015 Financial Results
5. Merrimack to Present Research on Multiple Programs at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Merrimack Announces Timing of Third Quarter 2015 Investor Conference Call
7. PharmaEngine Announces U.S. FDA Approves Merrimacks ONIVYDE(TM) (irinotecan liposome injection)
8. Merrimack Pharmaceuticals Names Dr. Yasir Al-Wakeel as Chief Financial Officer and Head of Corporate Development
9. Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call
10. Merrimack Pharmaceuticals Announces the Addition of John M. Dineen, Former CEO of GE Healthcare, to Its Board of Directors
11. Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... June 7, 2017 Endo International plc (NASDAQ: ... 2017, the Hon. Joseph R. Goodwin , U.S. ... West Virginia , entered a case management ... Repair System Products Liability Litigation (the "MDL") that includes ... to provide expert disclosures on specific causation within one ...
(Date:6/3/2017)... 3, 2017  Eli Lilly and Company (NYSE: ... from the Phase 3 MONARCH 2 study showed ... inhibitor, in combination with fulvestrant, significantly improved progression-free ... in women with hormone-receptor-positive (HR+), human epidermal growth ... have relapsed or progressed after endocrine therapy (median ...
(Date:5/30/2017)... May 30, 2017 Therapix Biosciences Ltd. (Nasdaq: ... in the development of cannabinoid-based drugs, today announced ... overview at three upcoming scientific and investor conferences ... Micro Invitational: ... Date:                     Wednesday, ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... "The Better Care Reconciliation Act ... harm to people with all chronic conditions, including mental illnesses, while increasing the ... the Affordable Care Act (ACA) requirement that insurers cover pre-existing conditions, it does ...
(Date:6/23/2017)... ... ... Studies show evidence that carotenoids and antioxidants derived either from the diet or from ... how often do ophthalmologists and optometrists in Sweden recommend the use of nutritional supplements, ... symptoms of AMD? A study published recently in Dove Medical Press journal, ...
(Date:6/23/2017)... ... June 23, 2017 , ... Military Connection friend and veteran ... the JFK Virgin Atlantic lounge. , Bensko is no stranger to the plight ... Bensko dedicated her life to supporting our wounded veterans. A world-class photographer, her riveting ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Aesthetic Channel has recently highlighted ... has come up with a proprietary technique that he calls the AuraLyft ... dropped. For all ages, patients can expect to look refreshed, rejuvenated, and revitalized. ...
(Date:6/23/2017)... ... ... 21 Middle East and South Asia Leaders Selected as Eisenhower Fellows , ... society in 11 countries across the Middle East and South Asia to embark on ... knowledge and ideas with the leading minds in their fields. , For the ...
Breaking Medicine News(10 mins):